NuCana

Ticker: NCNA

Sector: Biotechnology

NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product is NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil, which is in Phase 1b/2 trial for patients with advanced colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular trial in combination with the PD-1 inhibitor pembrolizumab for the treatment of patients with advanced solid tumors and in combination with docetaxel for the treatment of patients with lung cancer. The company also develops NUC-7738, a ProTide transformation of 3'-deoxyadenosine that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological malignancies. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.